 | | Vol. 12.27 – 16 July, 2020 |
| |
|
|
| Scientists showed that claudin-low breast cancers exhibited a significant diversity, comprising three main subgroups that emerged from unique evolutionary processes.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers found that Ccr2 deletion in cancer cells led to reduced tumor growth and approximately two-fold longer survival in an orthotopic, isograft breast cancer mouse model. Their overall results established that C-C chemokine receptor type 2 (CCR2) signaling in cancer cells could orchestrate suppression of the immune response.
[Journal of Experimental Medicine] |
|
|
|
| The authors describe the characterization of a novel circulating tumor cell (CTC)‐derived breast cancer cell line, designated CTC‐ITB‐01, established from a patient with metastatic estrogen receptor‐positive breast cancer, resistant to endocrine therapy.
[EMBO Molecular Medicine] |
|
|
|
| This study characterized the effects of unacylated ghrelin on breast cancer cells, defined its mechanism of action, and explored the therapeutic potential of unacylated ghrelin or analog AZP-531.
[eLife] |
|
|
|
| Scientists showed that progesterone receptor membrane component 1 might mediate proliferation and progression of breast cancer cells potentially by altering lipid metabolism and by activating key oncogenic signaling pathways, such as ERα expression and activation, as well as EGFR signaling.
[Breast Cancer Research] |
|
|
|
| Investigators demonstrated that changes in the expression of Yes-associated protein and β-catenin might be a promising predictive biomarker for neoadjuvant chemotherapy sensitivity in TNBC patients.
[Cell Death & Disease] |
|
|
|
| Researchers identified SOX9 protein as a “master regulator” of breast cancer cell survival and metastasis.
[Molecular Cancer Research] |
|
|
|
| The authors identified a novel mechanism of LINC00160‐mediated chemoresistance via the C/EBPβ/TFF3 axis, highlighting the potential of LINC00160 for treating breast cancer with chemoresistance.
[Journal of Cellular and Molecular Medicine] |
|
|
|
| Scientists provided evidence that TGF-β disrupted the lineage commitment and promoted the accumulation of tumor-initiating cells in pre-neoplastic cells.
[Scientific Reports] |
|
|
|
|
| This review focuses on conventional drug therapies, recent treatment strategies, and unique therapeutic approaches available for breast cancer and TNBC.
[Journal of Controlled Release] |
|
|
|
|
| Daiichi Sankyo Company, Limited announced that the European Medicines Agency has validated the Marketing Authorization Application for trastuzumab deruxtecan, a HER2 directed antibody drug conjugate, for the treatment of adults with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens.
[Daiichi Sankyo] |
|
|
|
| Some researchers worry students will miss out on certain practical and problem-solving skills and won’t be able to judge whether the hands-on work of a scientist is a good fit for them. But instructors are developing high-tech ways to simulate the field and lab experiences.
[Science Insider] |
|
|
|
|
| October 20 – October 21
Virtual |
|
|
|
|
|
| | Hackensack Meridian Health – Edison, New Jersey, United States |
|
|
|
| | Northwestern University – Chicago, Illinois, United States |
|
|
|
| | Mayo Clinic – Rochester, Minnesota, United States |
|
|
|
| | Georgetown University Medical Center – Washington, District of Columbia, United States |
|
|
|
| | University of Pittsburgh – Pittsburgh, Pennsylvania, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
